Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
Biohaven licensed its lead epilepsy drug opakalim to SK Biopharmaceuticals in a deal valued up to $795 million, providing $400 million in near-term cash to offset significant quarterly losses.
Chemours (CC) Enters the AI Cooling Market with New Refrigerants
Chemours launched two new refrigerants designed for data center cooling to address heat loads from AI infrastructure, offering both low-emissions and transitional options for different customer needs.
Helios Technologies (HLIO) Drives Its Electronics Growth Story Off-Road
Helios Technologies expanded its No Roads platform with Apple CarPlay and Android Auto integration for boats and off-road vehicles, alongside raised full-year guidance and significant Electronics segment margin expansion.
ChargePoint CEO says 70% stock surge ‘is the beginning of the momentum’
ChargePoint stock surged over 70% after beating second-quarter expectations and guiding toward continued performance improvements, with CEO Rick Wilmer calling it “the beginning of the momentum.”
Best Buy beats quarterly estimates and hikes its outlook, but stock falls
Best Buy reported better-than-expected fiscal second-quarter results and raised its full-year outlook, though its stock declined about 7% in morning trading.
Family offices are making a bullish bet on the stock market, according to CNBC Family Office Portfolio Tracker
Family offices increased stock holdings to 37% of portfolios in the second quarter, up from 34%, marking their largest quarterly shift in years and signaling bullish sentiment on equities and AI investments.